TX-PLANVIEW
24.8.2022 19:08:04 CEST | Business Wire | Press release
Planview , a global leader in Portfolio Management and Work Management, announced it has been named a Leader in the 2022 Gartner Magic Quadrant for Adaptive Project Management and Reporting 1 , based on its Ability to Execute and Completeness of Vision. This news follows previous announcements that Planview is a Leader in both the 2022 Gartner Magic Quadrant for Strategic Portfolio Management2 and the 2022 Gartner Magic Quadrant for Enterprise Agile Planning Tools3 .
Download a complimentary copy of the 2022 Gartner Magic Quadrant for Adaptive Project Management and Reporting (APMR).
According to Gartner, “There are separate and distinct technology solutions in the APMR and SPM markets. APMR technology solutions specialize in effective execution activities while also enabling transparency, reporting to the portfolio, and facilitating workgroup-level communication and collaboration. These tools can be used in small to large organizations, guided by a fit- for-purpose selection approach to ensure the optimal choice of a vendor product is in alignment with organizational readiness and APMR maturity.”
“Organizations are maturing from a single work methodology to embracing hybrid work styles as part of their transformation journey from traditional to modern project portfolio management,” said Louise Allen, chief product officer, Planview. “As the market continues to evolve, our vision is to help our customers connect their business from ideas to impact, empowering them to accelerate what matters most. Planview is the only vendor recognized as a Leader in the 2022 Magic Quadrants for Strategic Portfolio Management , Adaptive Project Management and Reporting , and Enterprise Agile Planning Tools , and we are thrilled to partner with our customers to adapt, be agile and constantly transform – wherever they are on their journey.”
To learn more about Planview’s Project Portfolio Management solutions, visit: https://www.planview.com/products-solutions/solutions/project-portfolio-management/ .
1 Gartner, Magic Quadrant for Adaptive Project Management and Reporting by Lorri Callahan, Sarah Davies, Daniel Stang, and Anthony Henderson, August 22, 2022.
2 Gartner, Magic Quadrant for Strategic Portfolio Management by Anthony Henderson and Daniel Stang, April 18, 2022.
3 Gartner, Magic Quadrant for Enterprise Agile Planning Tools by Bill Blosen, Mike West, Keith Mann, Deacon D.K. Wan, Akis Sklavounakis, Hassan Ennaciri, and Sarah Davies, April 25, 2022.
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
GARTNER, Magic Quadrant and Critical Capabilities are registered trademarks and service marks of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. All rights reserved.
About Planview
Planview has one mission: to build the future of connected work. Our solutions enable organizations to connect the business from ideas to impact, empowering companies to accelerate the achievement of what matters most. Planview’s full spectrum of Portfolio Management and Work Management solutions create an organizational focus on the strategic outcomes that matter and empower teams to deliver their best work, no matter how they work. The comprehensive Planview platform and enterprise success model enables customers to deliver innovative, competitive products, services, and customer experiences. Headquartered in Austin, Texas, with locations around the world, Planview has more than 1,300 employees supporting 4,500 customers and 2.6 million users worldwide. For more information, visit www.planview.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220824005531/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hisense Delivers 38% Sales Uplift in Western Europe Markets With NIQ’s AI-Powered Market Intelligence6.5.2026 05:00:00 CEST | Press release
NIQ insights drive international expansion and measurable growth for Hisense across key global markets NIQ (NYSE: NIQ), a global leader in consumer intelligence, today shared new learnings from its long-standing collaboration with Hisense, a leading global brand in home appliances and smart technologies. Using NIQ’s AI‑powered market intelligence, Hisense has accelerated international expansion, improved local market decision-making, and delivered measurable growth across more than 20 key markets and 12+ categories. The case study demonstrates how AI‑driven insights help global brands move faster, localize better, and compete more effectively in complex markets. The Challenge As Hisense expanded internationally, it faced rising complexity across global markets. Consumer preferences differed sharply across regions such as Western Europe, Eastern Europe, and Latin America, making a one‑size‑fits‑all approach ineffective. NIQ’s AI‑powered intelligence delivered the local market depth need
Samsung Bioepis Announces Positive Preliminary Phase 1 Data for SB27, Proposed Biosimilar to Keytruda (Pembrolizumab)6.5.2026 01:00:00 CEST | Press release
Phase 1 study has demonstrated pharmacokinetics (PK) equivalence between SB27 and KeytrudaPhase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 study on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), has met its primary pharmacokinetics (PK) endpoints. The randomized, double-blind, three-arm, parallel group, multicenter clinical trial demonstrated pharmacokinetic bioequivalence of SB27 (pembrolizumab) to the reference product Keytruda. Initiated in January 2024, Phase 1 study is being conducted in four countries, and is expected to be completed by November 2026.2 The study assessed pharmacokinetics, efficacy, safety, and immunogenicity of SB27, EU-sourced Keytruda, and US-sourced Keytruda in patients with stage II or IIIA non-small cell lung cancer (NSCLC) following complete resection and adjuvant platinum-based chemotherapy. 163 participants were randomized to receive SB27, EU-sourced Keytruda, or US-sour
Megaport Launches Built-In DDoS Protection Enabling On-Demand Network Resilience6.5.2026 00:00:00 CEST | Press release
Megaport DDoS Protection removes the trade-off between security, performance, and cost, offering rapid enterprise-grade mitigation. Megaport Limited (ASX: MP1) (“Megaport”), a leading global automated infrastructure platform, today announced the launch of Megaport DDoS Protection. This new, built-in security capability for Megaport Internet allows customers to filter malicious traffic directly within the Megaport network rather than routing it through a separate or external service, for mission-critical uptime without introducing additional latency or routing complexity. As enterprises increasingly migrate to distributed cloud environments, traditional DDoS mitigation has struggled to keep pace with cloud and distributed infrastructure adoption. Standard ISP solutions often resort to dropping all traffic and taking the service offline to protect the network, while external third-party providers force a "security detour" that reroutes traffic through public infrastructure, introducing s
IFF Reports First Quarter 2026 Results5.5.2026 22:23:00 CEST | Press release
Delivered solid top and bottom line Q1 resultsProgressing disciplined sale process for Food Ingredients businessReaffirms Full Year 2026 Financial Guidance IFF (NYSE: IFF) reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Consolidated Summary: Management Commentary “IFF is off to a solid start in 2026, with first quarter results that reflect the customer focus and operational execution we’ve been building across the company,” said Erik Fyrwald, CEO of IFF. “We delivered volume growth in all four segments, improved profitability, and generated strong cash flow in the first quarter. As we look ahead, we are maintaining a disciplined approach to how we are planning the balance of the year as the current operating environment remains unsettled. We remained focused on advancing our commercial and innovation pipelines, driving productivity, and working with customers to offset inflation. This – when combined with our solid start to the year – derisks t
Logitech Announces Q4 and Full Fiscal Year 2026 Results5.5.2026 22:06:00 CEST | Press release
Strong FY 2026 Demonstrates Strategy and Operating Principles Are Delivering SIX Swiss Exchange Ad hoc announcement pursuant to Art. 53 LR — Logitech International (SIX: LOGN) (Nasdaq: LOGI) today announced financial results for the fourth quarter and full Fiscal Year 2026. For Fiscal Year 2026: Sales were $4.84 billion, up 6 percent in US dollars and 4 percent in constant currency compared to the prior year. GAAP operating income was $775 million, up 18 percent compared to the prior year. Non-GAAP operating income was $911 million, up 18 percent compared to the prior year. GAAP earnings per share was $4.80, up 16 percent compared to the prior year. Non-GAAP EPS was $5.78, up 19 percent compared to the prior year. Cash flow from operations was $1.04 billion. The year-ending cash balance was $1.7 billion. The Company returned $768 million of cash to shareholders through its annual dividend payment and share repurchases. For Q4 Fiscal Year 2026: Sales were $1.09 billion, up 7 percent in
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom